Navigation Links
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Date:1/28/2008

Lopinavir/ritonavir tablet is the first and only co-formulated protease

inhibitor tablet approved for use in children with HIV

ABBOTT PARK, Ill., Jan. 28 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of a new, lower-strength tablet formulation of the company's leading HIV protease inhibitor, Kaletra(R) (lopinavir/ritonavir). In addition, the CHMP has adopted a positive opinion, in coordination with the World Health Organization (WHO), for Aluvia(R) (lopinavir/ritonavir), the tradename of the same lower-strength tablet formulation in developing countries.

The new lower-strength formulation is suitable for pediatric use and represents a significant breakthrough for clinicians and patients in developing countries, where more than 2 million of the estimated 2.3 million children worldwide with HIV/AIDS live. The first and only co-formulated protease inhibitor tablet that can be used in children, the tablets do not require refrigeration and can be taken with or without a meal -- an important advance in delivering HIV medicine in developing countries.

"EMEA approval is an essential first step to registering the tablet in Europe and most developing countries and it is welcome news for physicians and caregivers of children with HIV," said Mark Kline, M.D., professor of pediatrics, chief of Retrovirology, director, AIDS International Training and Research Program, and director, Baylor-CDC Global AIDS Technical Assistance Project, Baylor College of Medicine. "The development of this product, which does not require refrigeratio
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
2. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Actavis Launches Carvedilol Tablets in the U.S.
6. Mylan Announces Final FDA Approval for Carvedilol Tablets
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Actavis Launches Amlodipine Tablets in the U.S.
9. Tablet is better all round for cancer patients
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... modelling of the human eye, the brain of a ... and new technology, says a QUT leading robotics researcher. ... Engineering Faculty says the new study uses new computer ... high-density buildings or tunnels. , "This is a very ... putting two halves of a thing together because we,re ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 First Warning ... abnormal circadian cellular changes throughout the body, announced the ... to better address the company’s breadth of upcoming product ... breast cancer screening technology. , “Our initial focus will ... system which detects abnormal circadian cellular changes over time,” ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ 2.0 for ... is the bridge between the EHR and Dragon Medical ... information at the point of care. NoteSwift reduces the ... more than half – and virtually eliminates mouse clicks ... impedes EHR use according to the June 12, 2014 ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3
... said that it will announce a new brand of coffee ... 21 years of research, the CCRI expects to release the ... arabica variety is resistant to diseases such as leaf rust ... borer. ,CCRI officials said trials of the new ...
... again when she was pictured with baby bump . ... Travolta starrer Hairspray dressed in a figure-hugging black dress that ... ,Holmes sparked off rumours that she and hubby ... spotted with bump while visiting new best friends David and ...
... been ruled out of the entire Test series against India ... be out for four to six weeks, reports BBC . ... the hernia has come back and now it's all about ... Anderson, Stuart Broad and Chris Tremlett are vying for the ...
... Wednesday said the government was not averse to inviting the ... a mosquito borne fever in the state that has claimed ... expert teams have arrived in the state since the outbreak ... which have confirmed the fever as chikunguniya and nothing else, ...
... can overcome their problem by taking part in group ... ,The study also suggests that supplementing sildenafil, sold ... names, to group therapy can make the treatment more ... function relies on the coordination of psychological, endocrine, vascular, ...
... has reserved seats for students suffering from AIDS and cancer ... has reserved one seat for each of the fifty-six courses ... from cancer. ,However, the university feels that one ... time being, since it do not expects many patients queuing ...
Cached Medicine News:Health News:Harmison Ruled Out Off Test Series Due to Hernia 2
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... conducted by Dobson | DaVanzo & Associates found that ... (DME) may limit Medicare beneficiaries, access to home medical ... products that Medicare consumers rely on.   ... Americans who require oxygen equipment and therapy, mobility assistive ...
... Sept. 14, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) and Alkermes, Inc. (Nasdaq: ... on BYETTA® (exenatide) injection and the investigational product BYDUREON™ ... the 46th Annual Meeting of the European Association for ...
Cached Medicine Technology:Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 2Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 3Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 2BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 3BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 5BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 6BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 7
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Nucleus chopper. For bimanual nucleus division....
Medicine Products: